FDA
-
-
-
-
-
-
-
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
335,560 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


